1. Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2.
- Author
-
Elilarasi S, Poovazhagi V, Kumaravel G, Srividya VG, and Solomon JRS
- Subjects
- Child, Fever etiology, Humans, India epidemiology, Multiple Organ Failure, Systemic Inflammatory Response Syndrome diagnosis, Systemic Inflammatory Response Syndrome therapy, COVID-19 complications, COVID-19 diagnosis, SARS-CoV-2
- Abstract
Objectives: To know the clinical presentation and outcome of children with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV- 2 (PIMS-TS) at a pediatric tertiary care center in Chennai., Methods: Clinical and biochemical parameters of 65 children with PIMS-TS treated between July and October 2020 were studied. All children had their COVID RT-PCR and IgG COVID antibodies tests done., Results: Mean age of the study group was 5.65 ± 3.68 y. Fever with red eyes, rash, vomiting, abdominal pain, and shock were common presenting features. Sixty percent of the study group had Kawasaki/incomplete Kawasaki features. Sixty-seven percent of the study group had coronary dilatation, 41% presented with shock, and 25% had left ventricular dysfunction. Coronary aneurysms were documented in 58% of the study group (z score more than 2.5). Respiratory presentation with pneumonia was seen in 10%. Four children presented with acute abdomen. Acute kidney injury, acute liver failure, hemolysis, pancytopenia, macrophage activation syndrome, encephalopathy, and multiorgan dysfunction syndrome (MODS) were other features. Forty-three percent required noninvasive oxygen support and 15.4% required mechanical ventilation. Intravenous immunoglobulin (73.8%) and methylprednisolone (49.8%) were used for therapy. Mortality in the study was 6%, which was due to MODS., Conclusions: Acute febrile illness with mucocutaneous and gastrointestinal manifestations should have PIMS-TS as a possible differential diagnosis and needs evaluation with inflammatory markers and SARS-CoV-2 antibodies., (© 2021. Dr. K C Chaudhuri Foundation.)
- Published
- 2022
- Full Text
- View/download PDF